Indications and uses
to temporarily relieve symptoms commonly associated with PMS, such as: exhaustion dullness drowsiness muscle weakness
to temporarily relieve symptoms commonly associated with PMS, such as: exhaustion dullness drowsiness muscle weakness
Dispense Premensa directly into mouth, or add recommended dosage into 8-12 oz purified (non-chlorinated) water and drink. Safe for ages 2 and up.
do not use if tamper seal is broken store in a cool, dry place product must not come in contact with metal do not store next to electrical devices or appliances
Apis mellifica HPUS
Chamomilla HPUS
Cimicifuga racemosa HPUS
Cyclamen europaeum HPUS
Helonias dioica HPUS
Ignatia amara HPUS
Lac caninum HPUS
Lycopodium clavatum HPUS
Natrum muriaticum HPUS
Nux vomica HPUS
Platinum metallicum HPUS
Sepia HPUS
Each active ingredient contains equal volumes of 10X, 30X, and LM1 potencies. The letters “HPUS” indicate that the components in this product are officially monographed in the Homeopathic Pharmacopoeia of the United States. Product indications are based on Homeopathic Materia Medica. Product indications are based on Homeopathic Materia Medica.
Apis mellifica HPUS..…………………………Cramps
Chamomilla HPUS…………………………….Sensitivity
Cimicifuga racemosa HPUS.……………......Migraines
Cyclamen europaeum HPUS………….….....Headaches
Helonias dioica HPUS………………………..Pain/weakness
Ignatia amara HPUS.…………………..……..Mood swings
Lac caninum HPUS.…………………………..Weakness
Lycopodium clavatum HPUS..…..……….....Excessive hunger
Natrum muriaticum HPUS…………………....Water retention
Nux vomica HPUS…………………………….Sensitivity
Platinum metallicum HPUS……………….....Irritability
Sepia HPUS……………..……………………..Hot flashes
to temporarily relieve symptoms commonly associated with PMS, such as:
Ask a doctor before use if
When using this product use only as directed.
Stop use and ask a doctor if symptoms persist or worsen.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of the reach of children.
Dispense Premensa directly into mouth, or add recommended dosage into 8-12 oz purified (non-chlorinated) water and drink. Safe for ages 2 and up.
1 mL twice per day
-or as needed*
*Excessive dosing may cause mild digestive discomfort.
citric acid, potassium sorbate, purified ionized mineral water.
You can email us at
info@hellolife.net or call us toll-free at
1.800.875.0850 Monday through Friday, 9am-5pm ET.
Mftd for: HelloLife, Inc.
4460 44th St. SE, Ste. C-600
Grand Rapids, MI 49512
FDA Pharmaceutical Establishment
#1053442,
#3009727070
www.premensa.com
NDC 49726-016-02
PREMENSA®
PMS Symptom Relief
To temporarily relieve symptoms commonly associated with PMS, such as:
2 fl. oz (59 mL)
Homeopathic (OTC) Medicine
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 49726-016-02 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-f943-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 49726-016-02 | PremensaPMS Symptom Relief | 1 in 1 CARTON | LIQUID | 1 | 10 | |
| 49726-016-02 | PremensaPMS Symptom Relief | 59 mL in 1 BOTTLE, DROPPER | LIQUID | 59 | 10 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 49726-016 | PREMENSA PMS SYMPTOM RELIEF (APIS MELLIFICA, CHAMOMILLA, CIMICIFUGA RACEMOSA, CYCLAMEN EUROPAEUM, HELONIAS DIOCA, IGNATIA AMARA, LAC CANINUM, LYCOPODIUM CLAVATUM, NATRUM MURIATICUM, NUX VOMICA, PLATINUM METALLICUM, SEPIA) LIQUID [HELLO LIFE, INC.] | 10 | Legacy NDC, 2 package rows | 20181227_0f99bbef-6239-41cd-96ac-312a79627efd.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| APIS MELLIFERA | ACTIVE INGREDIENT | 7S82P3R43Z | 8 | |
| BLACK COHOSH | ACTIVE INGREDIENT | K73E24S6X9 | 8 | |
| CANIS LUPUS FAMILIARIS MILK | ACTIVE INGREDIENT | G39P120JQT | 8 | |
| CHAMAELIRIUM LUTEUM ROOT | ACTIVE INGREDIENT | DQV54Y5H3U | 8 | |
| CHAMOMILE | ACTIVE INGREDIENT | FGL3685T2X | 8 | |
| CYCLAMEN PURPURASCENS TUBER | ACTIVE INGREDIENT | G728143D8Q | 8 | |
| LYCOPODIUM CLAVATUM SPORE | ACTIVE INGREDIENT | C88X29Y479 | 8 | |
| PLATINUM | ACTIVE INGREDIENT | 49DFR088MY | 8 | |
| SEPIA OFFICINALIS JUICE | ACTIVE INGREDIENT | QDL83WN8C2 | 8 | |
| SODIUM CHLORIDE | ACTIVE INGREDIENT | 451W47IQ8X | 8 | |
| STRYCHNOS IGNATII SEED | ACTIVE INGREDIENT | 1NM3M2487K | 8 | |
| STRYCHNOS NUX-VOMICA SEED | ACTIVE INGREDIENT | 269XH13919 | 8 | |
| APIS MELLIFERA | ACTIVE MOIETY | 7S82P3R43Z | 8 | |
| BLACK COHOSH | ACTIVE MOIETY | K73E24S6X9 | 8 | |
| CANIS LUPUS FAMILIARIS MILK | ACTIVE MOIETY | G39P120JQT | 8 | |
| CHAMAELIRIUM LUTEUM ROOT | ACTIVE MOIETY | DQV54Y5H3U | 8 | |
| CHAMOMILE | ACTIVE MOIETY | FGL3685T2X | 8 | |
| CYCLAMEN PURPURASCENS TUBER | ACTIVE MOIETY | G728143D8Q | 8 | |
| LYCOPODIUM CLAVATUM SPORE | ACTIVE MOIETY | C88X29Y479 | 8 | |
| PLATINUM | ACTIVE MOIETY | 49DFR088MY | 8 | |
| SEPIA OFFICINALIS JUICE | ACTIVE MOIETY | QDL83WN8C2 | 8 | |
| SODIUM CATION | ACTIVE MOIETY | LYR4M0NH37 | 8 | |
| STRYCHNOS IGNATII SEED | ACTIVE MOIETY | 1NM3M2487K | 8 | |
| STRYCHNOS NUX-VOMICA SEED | ACTIVE MOIETY | 269XH13919 | 8 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 8 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | 8 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 8 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 49726-016 | 49726-016-02 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, COATED / ORAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / NASAL | 2.8 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAOCULAR | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / SUBCUTANEOUS | 26 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | FILM, EXTENDED RELEASE / TRANSDERMAL | 1.38 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CREAM / TOPICAL | 0.25 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRABURSAL | ADJ PH | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | EMULSION / OPHTHALMIC | 0.47 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / RESPIRATORY (INHALATION) | 0.03 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAPLEURAL | ADJ PH | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | LOTION / TOPICAL | 0.2 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CONCENTRATE / ORAL | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | DOUCHE / VAGINAL | 0.07 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SWAB / TOPICAL | 0.05 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | OINTMENT / TOPICAL | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | EMULSION / TOPICAL | 0.11 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SPRAY, METERED / NASAL | 0.06 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / ORAL | 315 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET / ORAL | 6 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / SUBCUTANEOUS | 28 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYRUP / ORAL | 722 mg/5ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / TOPICAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION, EXTENDED RELEASE / ORAL | 140.8 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LIQUID / ORAL | 114 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOAP / TOPICAL | 0.5 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INFILTRATION | 0.02 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, FILM COATED / ORAL | 42 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / BUCCAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / IONTOPHORESIS | 0.2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | GRANULE, FOR SUSPENSION / ORAL | 113 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / EPIDURAL | 0.02 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAMUSCULAR | 26 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRATHECAL | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAVENOUS | 10 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | PASTE / ORAL | 48 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET / SUBLINGUAL | 24 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / RECTAL | 7 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | AEROSOL, FOAM / TOPICAL | 8 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, COATED / ORAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SHAMPOO / TOPICAL | 17 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CONCENTRATE / ORAL | 5.3 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / ORAL | 269 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INHALANT / RESPIRATORY (INHALATION) | NA | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SUSPENSION / ORAL | 400 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CREAM / VAGINAL | 0.49 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / OPHTHALMIC | 0.03 %w/v | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | GRANULE, FOR SUSPENSION / ORAL | 80 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, CHEWABLE / ORAL | 7 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LOTION / TOPICAL | 0.85 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, EFFERVESCENT / ORAL | 460 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 385 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | ELIXIR / ORAL | 100 mg/5ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / AURICULAR (OTIC) | 0.2 %w/v | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION / RECTAL | 6.67 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | FILM / SUBLINGUAL | 10 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRAMUSCULAR | 28 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRALESIONAL | ADJ PH | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION/ DROPS / ORAL | 19 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 608 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 7df0b4ca-2f66-e8e5-e053-2991aa0af9ee | 0f99bbef-6239-41cd-96ac-312a79627efd | 2018-12-26 | Warnings | 7df0b4ca-2f66-e8e5-e053-2991aa0af9ee 0f99bbef-6239-41cd-96ac-312a79627efd |
Adverse event summaries are temporarily unavailable. Other product information remains available.